Chinese

advanced search

Medical Cooperation

Home Cooperation & Exchange Medical Cooperation Content

Our hospital signed the Memorandum of Understanding for Strategic Cooperation with Janssen (China) R&D of Johnson & Johnson (China) Investment Ltd.

Updated: Mar 26, 2021
From: Party Office
Edited by: Liu Huiting
Hits:

On the morning of March 23, the signing ceremony of the Memorandum of Understanding for Strategic Cooperation between the First Affiliated Hospital of Xi’an Jiaotong University (XJTU) and Janssen (China) R&D of Johnson & Johnson (China) Investment Ltd. was held in our hospital. Yan Hong, Vice President of XJTU, Liu Na, Deputy Director of Hospital Administration Bureau of Health Commission of Shaanxi Province, Shi Bingyin, President of our hospital, Vice President Wang Maode, Assistant-to-President Han Jianfeng, directors of relevant departments and clinical experts attended the signing ceremony. Li Zili, Vice President of Global Drug Development in Janssen Pharmaceuticals of Johnson & Johnson Group and Head of Asia-Pacific R&D, Li Bin, Head of Medical Affairs of Xi 'an Janssen and relevant representatives attended the event. The signing ceremony was presided over by Vice President Wang Maode.

President Shi Bingyin gave a welcome speech. He emphasized the importance of scientific and technological innovation in national strategic layout and high-quality development, and introduced the development status and representative research outcomes of scientific research in our hospital. Bilateral sides will complement each other in talent training, promotion of scientific research and regional development, promote the rapid transformation of clinical trials, accelerate the development of our hospital in the new era and make more innovative drugs accessible to Chinese patients at an earlier time.

Li Zili, Vice President of Global Drug Development in Janssen Pharmaceuticals of Johnson & Johnson Group and Head of Asia-Pacific R&D delivered a speech, highlighting that the strategic concept of innovative development of Johnson & Johnson Group is in line with the target of becoming a research hospital of the First Affiliated Hospital of XJTU. We, Janssen (China) R&D of Johnson & Johnson (China) Investment Ltd., would like to make a difference and we can do it. We expect to continue to cooperate with the First Affiliated Hospital of XJTU in a wide range of fields, explore novel research and development models, promote the rapid growth of bilateral sides and celebrate the centenary of the founding of the Communist Party of China.

Subsequently, President Shi Bingyin and Vice President Li Zili signed the Memorandum of Understanding for Strategic Cooperation on behalf of bilateral sides.

Liu Na, Deputy Director of Hospital Administration Bureau of Health Commission of Shaanxi Province, congratulated on the upcoming comprehensive strategic cooperation between two sides. She added that Health Commission of Shaanxi Province attaches great importance to the scientific research work of our hospital, expecting that both sides can take this signing ceremony as an opportunity to comprehensively promote the construction of Healthy Shaanxi and Healthy China, create a new wave of high-quality development and give Shaanxi province a head start during the 14thFive-Year Plan period.

Yan Hong, Vice President of XJTU, stressed that two sides joins hands again and can definitely achieve broader development by intimately adhering to the national development strategy. Upholding the global perspective, Innovation Port of XJTU is accelerating the "6352" project and building up a "special zone" for scientific and technological innovation. MED-X Research Institute of Innovation Port has huge potential for growth and development. We hope that bilateral sides can broaden the ways of thinking, deliver exchanges and discussions on a regular basis, carry out in-depth cooperation in different fields and facilitate the cooperation between two sides to a new stage of development.

During the exchange meeting, bilateral sides delivered exchanges and discussions regarding talent training, transformation of clinical trials and outcomes. Both sides reached a preliminary consensus on the willingness and patterns of mutual cooperation.


Next:Our hospital holds a strategic cooperation seminar with Janssen (China) R&D of Johnson &Johnson Group

Copyright (c) 2011, First Affiliated Hospital of Xi 'an Jiaotong University Shaanxi ICP for 12009712-3